Dr Kim Linton

Overview

Dr Linton is a Clinical Senior Lecturer in the Division of Molecular & Clinical Cancer Sciences at The University of Manchester, and an honorary Consultant in Medical Oncology at The Christie NHS Foundation Trust.  She has a specialist interest in the clinical management of lymphoma and, since her consultant appointment in 2009, has been local principal investigator on over 50 industry- and investigator-led clinical trials, with an extensive lymphoma trials portfolio from first-in-man to late phase clinical drug development.  She currently serves on the trial management group for 4 UK NCRI trials and is UK lead investigator for several industry-sponsored international clinical trials. She is also leading on several real world observational studies in follicular and mantle cell lymphoma and has authored over 50 peer reviewed publications, including numerous practice and consensus lymphoma guidelines.

She holds national and international leadership postitions, including her role as chair of the UK NCRI Low Grade Lymphoma Subgroup and Chair elect for the Manchester Lymphoma Group. She is a member of the NCRI Lymphoma Research Group, Lymphoma Science and High Grade subgroups and several working parties, as well as being a medical advisor for Lymphoma Action,  Scientific Secretary to the European Heamatology Association Lymphoma Scientific Working Party, and steering committee member for Women in Lymphoma, a global organisation. She has a clinical interest in advanced cellular therapies and co-leads a work package within iMATCH (Innovate Manchester Advanced Therapy Centre Hub).  She provides external consultancy for the Pharma Industry and National Institute for Health and Care Excellence (NICE) and serves on steering committees for Genmab and Roche pharmaceutical companies.

Dr Linton has a PhD in Molecular Pathology from The University of Manchester and runs a programme of translational research at the Manchester Cancer Research Centre, focussed on lymphoma biomarker development and late effects of lymphoma treatment. Current and future projects include development of lung cancer screening programmes in Hodgkin Lymphoma survivors, biomarkers for cardiovascular toxicity following anthracyclines and novel prognostic biomarkers in Follicular and Hodgkin Lymphoma.  She chairs the second cancers theme for the BRC Living With and Beyond Cancer Sciences Centre. 

Dr Linton is a clinical and educational supervisor for speciality and academic foundation trainees in medical oncology and examiner and supervisor for doctoral and masters dissertations. She serves on the MRes Oncology Programme committee and co-leads the Clinical Masterclass Module. She lectures on several University of Manchester and external accredited courses, including the Oxford Lymphoma Management Course.

Biography

Dr Linton was awarded a medical degree from the University of Cape Town in 1994. She joined The Christie as a Specialist Registrar in 2000 and obtained a PhD in molecular pathology from the University of Manchester in  2007. She was appointed to her current role in 2009 as Clinical Senior Lecturer and Honorary Consultant in Medical Oncology at The University of Manchester and Christie NHS Fondation Trust, respectively. The was elected as a fellow of the Royal College of Physicians in 2020.

Qualifications

MBChB (University of Cape Town, 1994)

MRCP (Edinburgh, 1999)

PhD (The University of Manchester, 2007)

FRCP (London, 2020)

Memberships of committees and professional bodies

• Women in Lymphoma
• Epcoritamab Global Council
• EHA Lymphoma Scientific Working Group
• NCRI Lymphoma Research Group, Low Grade Lymphoma Subgroup, Science subgroup, High Grade Subgroup, T cell working party, PCNSL working party
• Lymphoma Action Medical Advisory Panel
• NICE Centre for Guidelines (CfG)
• Roche Haematology Steering Group
• BSH Special Interests Group (completed 2020)
• Manchester Lymphoma Group
• MRes Oncology Board
• British Committee for Standards in Haematology Guideline Writing Committees
• Royal College of Physicians
• Association of Cancer Physicians
• Medical Protection Society